Fly News Breaks for February 5, 2020
Feb 5, 2020 | 08:47 EDT
BTIG analyst Ryan Zimmerman raised his price target on Zimmer Biomet to $170 and kept his Buy rating after its Q4 earnings beat. The analyst says the quarter showed "encouraging growth" in key reconstruction areas, and he believes that the company will continue investing to target mid-single-digit revenue growth. Zimmerman adds that with improving top-line performance and longer-term operating margin goals, he believes that investors are gaining increased confidence in Zimmer's potential for longer-term earnings growth.
News For ZBH From the Last 2 Days
There are no results for your query ZBH